ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2959

Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout

Tony R. Merriman1, Marilyn E. Merriman1, Ruth Topless1, Sara Altaf2, Grant Montgomery3, Christopher Franklin4, Gregory T. Jones5, Andre M. van Rij2, Douglas HN White6, Lisa K. Stamp7, Nicola Dalbeth8 and Amanda Phipps-Green1, 1Department of Biochemistry, University of Otago, Dunedin, New Zealand, 2University of Otago, Dunedin, New Zealand, 3Queensland Institute of Medical Research, Brisbane, Australia, 4University of Auckland, Auckland, New Zealand, 5Surgery, University of Otago, Dunedin, New Zealand, 6Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7University of Otago, Christchurch, New Zealand, 8Department of Medicine, University of Auckland, Auckland, New Zealand

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: genetics, Gout and uric acid

  • Tweet
  • Email
  • Print
Session Information

Title: Metabolic and Crystal Arthropathies II: Mechanisms of Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Twenty-eight genetic loci are associated with serum urate levels in Europeans. Ten are established, with a further 18 of weaker effect more recently detected. SLC2A9, ABCG2, SLC17A1 and GCKR, with stronger effect sizes, have been consistently associated with gout. Evidence for association with gout at the other 24 loci is absent, equivocal or not replicated, with one explanation likely to be non-clinical ascertainment of gout. Our aim was to test the loci with prevalent gout meeting the ACR gout classification criteria in Aotearoa New Zealand (NZ) European and Polynesian case-control sample sets.

Methods: 648 NZ European cases and 1550 controls, and 888 Polynesian (Māori and Pacific) cases and 1095 controls were genotyped. Association with gout was tested by logistic regression adjusting for age and sex, and ancestry estimate for Polynesians. Power was adequate (>0.7) to detect effects of OR>1.3.

Results: We focused on the 24 loci without consistent evidence for association with gout. Association was detected at seven loci in Europeans, one of which was the first report of association with gout (IGFR1) (Figure). In combined Polynesians association with gout was detected at three loci (SLC22A12, SFMBT1, VEGFA). Meta-analysis of Europeans and Polynesians revealed association at nine loci, two which had not previously been associated with gout (PDZK1 and MAF). In participants with higher Polynesian ancestry, there was association in an opposing direction to Europeans at PRKAG2 and HLF (Figure). In Europeans there was obvious inconsistency of gout association at four loci (GCKR, INHBC, SLC22A11, SLC16A9) that display very similar effects on urate levels.

Conclusion: We provide the first evidence for association with gout at four (IGRF1, PDZK1, MAF, HLF) serum urate loci not previously associated with gout. Understanding reasons for lack of correlation between urate and gout effect sizes will be important in understanding the etiology of urate control and risk of gout.

Reference: Kottgen et al. Nat Genet. 2013;45:145-54.

Figure Adjusted odds ratio of association of 28 serum loci with gout in NZ Europeans (yellow) and people with higher Polynesian ancestry (blue). Serum urate effect sizes taken from Kottgen et al. are shown (green triangles). * P ² 0.05, ** P ² 0.01, *** P ² 0.001, **** P ² 0.0001.


Disclosure:

T. R. Merriman,
None;

M. E. Merriman,
None;

R. Topless,
None;

S. Altaf,
None;

G. Montgomery,
None;

C. Franklin,
None;

G. T. Jones,
None;

A. M. van Rij,
None;

D. H. White,
None;

L. K. Stamp,
None;

N. Dalbeth,

Ardea,

5,

AstraZeneca,

5,

Takeda,

5,

Metabolex,

5,

Menarini,

8,

Savient,

8,

Novartis Pharmaceutical Corporation,

8,

Fonterra,

2,

Novartis Pharmaceutical Corporation,

2,

Ardea,

2,

Fonterra,

9;

A. Phipps-Green,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/twenty-eight-loci-that-influence-serum-urate-levels-analysis-of-association-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology